208 related articles for article (PubMed ID: 22548447)
1. Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling.
Haase HS; Peterson-Kaufman KJ; Lan Levengood SK; Checco JW; Murphy WL; Gellman SH
J Am Chem Soc; 2012 May; 134(18):7652-5. PubMed ID: 22548447
[TBL] [Abstract][Full Text] [Related]
2. Targeting diverse protein-protein interaction interfaces with α/β-peptides derived from the Z-domain scaffold.
Checco JW; Kreitler DF; Thomas NC; Belair DG; Rettko NJ; Murphy WL; Forest KT; Gellman SH
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4552-7. PubMed ID: 25825775
[TBL] [Abstract][Full Text] [Related]
3. Iterative Nonproteinogenic Residue Incorporation Yields α/β-Peptides with a Helix-Loop-Helix Tertiary Structure and High Affinity for VEGF.
Checco JW; Gellman SH
Chembiochem; 2017 Feb; 18(3):291-299. PubMed ID: 27897370
[TBL] [Abstract][Full Text] [Related]
4. Conformationally Constrained Peptides with High Affinity to the Vascular Endothelial Growth Factor.
Guryanov I; Korzhikov-Vlakh V; Bhattacharya M; Biondi B; Masiero G; Formaggio F; Tennikova T; Urtti A
J Med Chem; 2021 Aug; 64(15):10900-10907. PubMed ID: 34269584
[TBL] [Abstract][Full Text] [Related]
5. Peptide Lv augments L-type voltage-gated calcium channels through vascular endothelial growth factor receptor 2 (VEGFR2) signaling.
Shi L; Ko S; Ko ML; Kim AJ; Ko GY
Biochim Biophys Acta; 2015 May; 1853(5):1154-64. PubMed ID: 25698653
[TBL] [Abstract][Full Text] [Related]
6. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
7. Foldamers with heterogeneous backbones.
Horne WS; Gellman SH
Acc Chem Res; 2008 Oct; 41(10):1399-408. PubMed ID: 18590282
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the complex between VEGF and a receptor-blocking peptide.
Wiesmann C; Christinger HW; Cochran AG; Cunningham BC; Fairbrother WJ; Keenan CJ; Meng G; de Vos AM
Biochemistry; 1998 Dec; 37(51):17765-72. PubMed ID: 9922142
[TBL] [Abstract][Full Text] [Related]
9. Disrupting VEGF-VEGFR1 Interaction: De Novo Designed Linear Helical Peptides to Mimic the VEGF
Balsera B; Bonache MÁ; Reille-Seroussi M; Gagey-Eilstein N; Vidal M; González-Muñiz R; Pérez de Vega MJ
Molecules; 2017 Oct; 22(11):. PubMed ID: 29143774
[TBL] [Abstract][Full Text] [Related]
10. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
[TBL] [Abstract][Full Text] [Related]
11. Structural consequences of beta-amino acid preorganization in a self-assembling alpha/beta-peptide: fundamental studies of foldameric helix bundles.
Price JL; Horne WS; Gellman SH
J Am Chem Soc; 2010 Sep; 132(35):12378-87. PubMed ID: 20718422
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of diverse α/β-backbone patterns for functional α-helix mimicry: analogues of the Bim BH3 domain.
Boersma MD; Haase HS; Peterson-Kaufman KJ; Lee EF; Clarke OB; Colman PM; Smith BJ; Horne WS; Fairlie WD; Gellman SH
J Am Chem Soc; 2012 Jan; 134(1):315-23. PubMed ID: 22040025
[TBL] [Abstract][Full Text] [Related]
13. Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide.
D'Andrea LD; Iaccarino G; Fattorusso R; Sorriento D; Carannante C; Capasso D; Trimarco B; Pedone C
Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14215-20. PubMed ID: 16186493
[TBL] [Abstract][Full Text] [Related]
14. Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.
Horne WS; Johnson LM; Ketas TJ; Klasse PJ; Lu M; Moore JP; Gellman SH
Proc Natl Acad Sci U S A; 2009 Sep; 106(35):14751-6. PubMed ID: 19706443
[TBL] [Abstract][Full Text] [Related]
15. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904
[TBL] [Abstract][Full Text] [Related]
16. New Class of Drug Modalities: Directed Evolution of a De Novo Designed Helix-Loop-Helix Peptide to Bind VEGF for Tumor Growth Inhibition.
Michigami M; Ramanayake Mudiyanselage TMR; Suzuki M; Ishizako H; Notsu K; Sugiura K; Fujii I
ACS Chem Biol; 2022 Mar; 17(3):647-653. PubMed ID: 35176860
[TBL] [Abstract][Full Text] [Related]
17. α-Helix mimicry with α/β-peptides.
Johnson LM; Gellman SH
Methods Enzymol; 2013; 523():407-29. PubMed ID: 23422441
[TBL] [Abstract][Full Text] [Related]
18. Novel short peptides isolated from phage display library inhibit vascular endothelial growth factor activity.
Erdag B; Balcioglu KB; Kumbasar A; Celikbicak O; Zeder-Lutz G; Altschuh D; Salih B; Baysal K
Mol Biotechnol; 2007 Jan; 35(1):51-63. PubMed ID: 17401149
[TBL] [Abstract][Full Text] [Related]
19. The Inorganic Perspective of VEGF: Interactions of Cu(2+) with Peptides Encompassing a Recognition Domain of the VEGF Receptor.
Grasso G; Santoro AM; Magrì A; La Mendola D; Tomasello MF; Zimbone S; Rizzarelli E
J Inorg Biochem; 2016 Jun; 159():149-58. PubMed ID: 27015654
[TBL] [Abstract][Full Text] [Related]
20. VEGFR2 Mimicking Peptide Inhibits the Proliferation of Human Umbilical Vein Endothelial Cells (Huvecs) by Blocking VEGF.
Ghasemali S; Barzegar A; Farajnia S; Rahmati M; Negahdari B; Etemadi A; Nazari A
Anticancer Agents Med Chem; 2023; 23(14):1678-1688. PubMed ID: 37194933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
